ClinicalTrials.Veeva

Menu

Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer

A

ABC Foundation (FUABC)

Status

Unknown

Conditions

Breast Cancer
Fatigue

Study type

Observational

Funder types

Other

Identifiers

NCT02041364
Biomarker fatigue ABC001

Details and patient eligibility

About

Fatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand the mechanism of fatigue and search for potential biomarkers, we will conduct a prospective study with breast cancer patients receiving adjuvant chemotherapy.

Full description

Patients with breast cancer undergoing adjuvant systemic chemotherapy based on the use of anthracyclines will be screened before the start of chemotherapy.

Patients whose scores on the brief fatigue inventory (BFI) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue. The patients whose fatigue won't worse following the first cycle of chemotherapy will be used as controls. We will collect blood samples of both groups before and 21 days after the start of chemotherapy. We will analyze the following biomarkers: IL2, IL10, TNF and TGFB-1 measured by amplification reaction; FSH, LH, estradiol, DHEA, DHEAS and cortisol hormones measured by chemiluminescent enzyme immunometric assay

Enrollment

45 estimated patients

Sex

Female

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Non metastatic breast cancer;
  • Patients undergoing adjuvant chemotherapy

Exclusion criteria

  • hypothyroidism;
  • Depression;
  • anemia;
  • heart disease or decompensated hypertension

Trial design

45 participants in 2 patient groups

Control: patients without fatigue
Description:
Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
Patients with fatighe
Description:
Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue

Trial contacts and locations

1

Loading...

Central trial contact

Felipe M Cruz, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems